PepGen Inc. – NASDAQ:PEPG

PepGen stock price today

$1.24
-2.67
-68.37%
Financial Health
0
1
2
3
4
5
6
7
8
9

PepGen stock price monthly change

-76.72%
month

PepGen stock price quarterly change

-76.72%
quarter

PepGen stock price yearly change

-44.87%
year

PepGen key metrics

Market Cap
120.60M
Enterprise value
14.81M
P/E
-2.74
EV/Sales
N/A
EV/EBITDA
-0.15
Price/Sales
N/A
Price/Book
0.95
PEG ratio
0.10
EPS
-3.24
Revenue
N/A
EBITDA
-85.37M
Income
-80.32M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

PepGen stock price history

PepGen stock forecast

PepGen financial statements

PepGen Inc. (NASDAQ:PEPG): Profit margin
Jun 2023 0 -19.52M
Sep 2023 0 -23.29M
Dec 2023 1.66M -19.49M -1174.4%
Mar 2024 0 -18.02M
PepGen Inc. (NASDAQ:PEPG): Analyst Estimates
Dec 2023 1.66M -19.49M -1174.4%
Mar 2024 0 -18.02M
Oct 2025 0 -17.25M
Dec 2025 0 -17.40M
  • Analysts Price target

  • Financials & Ratios estimates

PepGen Inc. (NASDAQ:PEPG): Earnings per share (EPS)
2023-11-08 -0.88 -0.98
2024-03-06 -1.01 -0.82
2024-05-14 -0.74 -0.63
PepGen Inc. (NASDAQ:PEPG): Debt to assets
Jun 2023 182085000 34.80M 19.11%
Sep 2023 164271000 38.40M 23.38%
Dec 2023 143052000 34.63M 24.21%
Mar 2024 207000000 28.00M 13.53%
PepGen Inc. (NASDAQ:PEPG): Cash Flow
Jun 2023 -17.67M -1.00M 189
Sep 2023 -16.47M -225K -534
Dec 2023 -19.42M -29.58M 26
Mar 2024 -22.53M -11.29M 86.96M

PepGen alternative data

PepGen Inc. (NASDAQ:PEPG): Employee count
Aug 2023 49
Sep 2023 54
Oct 2023 54
Nov 2023 54
Dec 2023 63
Jan 2024 63
Feb 2024 63
Apr 2024 64
May 2024 64
Jun 2024 65
Jul 2024 65

PepGen other data

24.37% -47.84%
of PEPG is owned by hedge funds
3.81M -13.20M
shares is hold by hedge funds

PepGen Inc. (NASDAQ:PEPG): Insider trades (number of shares)
Period Buy Sel
Jun 2023 0 31250
Nov 2023 1694 0
Feb 2024 2557593 0
May 2024 0 10000
Transaction Date Insider Security Shares Price per share Total value Source
Sale
SVENSTRUP NIELS officer: SVP, Chem. Mfg & Contr..
Common Stock 10,000 $13.41 $134,100
Purchase
RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner:
Common Stock 2,557,593 $10.64 $27,212,790
Purchase
MCARTHUR JAMES G director, officer: President an..
Common Stock 1,694 $4.17 $7,056
Option
MCARTHUR JAMES G director, officer: President an..
Common Stock 2,381 $2.71 $6,453
Sale
MCARTHUR JAMES G director, officer: President an..
Common Stock 2,381 $16.04 $38,189
Option
MCARTHUR JAMES G director, officer: President an..
Stock Option (Right to Buy) 2,381 $2.71 $6,453
Option
MCARTHUR JAMES G director, officer: President an..
Common Stock 8,419 $2.71 $22,815
Sale
MCARTHUR JAMES G director, officer: President an..
Common Stock 8,419 $16.23 $136,615
Option
MCARTHUR JAMES G director, officer: President an..
Stock Option (Right to Buy) 8,419 $2.71 $22,815
Option
MCARTHUR JAMES G director, officer: President an..
Common Stock 18,150 $2.71 $49,187
Sunday, 29 December 2024
accesswire.com
Friday, 27 December 2024
prnewswire.com
Thursday, 26 December 2024
accesswire.com
Tuesday, 24 December 2024
accesswire.com
Tuesday, 17 December 2024
accesswire.com
Monday, 16 December 2024
https://thefly.com
Thursday, 21 November 2024
businesswire.com
Monday, 4 November 2024
businesswire.com
Thursday, 3 October 2024
accesswire.com
Wednesday, 2 October 2024
accesswire.com
Tuesday, 1 October 2024
accesswire.com
Monday, 30 September 2024
accesswire.com
Sunday, 29 September 2024
accesswire.com
Saturday, 28 September 2024
accesswire.com
Friday, 27 September 2024
accesswire.com
Thursday, 26 September 2024
accesswire.com
Wednesday, 25 September 2024
accesswire.com
Tuesday, 24 September 2024
accesswire.com
Monday, 23 September 2024
accesswire.com
Sunday, 22 September 2024
accesswire.com
Saturday, 21 September 2024
accesswire.com
Friday, 20 September 2024
accesswire.com
Thursday, 19 September 2024
businesswire.com
accesswire.com
Wednesday, 18 September 2024
accesswire.com
Tuesday, 17 September 2024
accesswire.com
Monday, 16 September 2024
accesswire.com
Sunday, 15 September 2024
accesswire.com
Saturday, 14 September 2024
accesswire.com
Friday, 13 September 2024
accesswire.com
  • What's the price of PepGen stock today?

    One share of PepGen stock can currently be purchased for approximately $1.24.

  • When is PepGen's next earnings date?

    Unfortunately, PepGen's (PEPG) next earnings date is currently unknown.

  • Does PepGen pay dividends?

    No, PepGen does not pay dividends.

  • How much money does PepGen make?

    PepGen has a market capitalization of 120.60M. PepGen made a loss 78.63M US dollars in net income (profit) last year or -$0.63 on an earnings per share basis.

  • What is PepGen's stock symbol?

    PepGen Inc. is traded on the NASDAQ under the ticker symbol "PEPG".

  • What is PepGen's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of PepGen?

    Shares of PepGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does PepGen have?

    As Jul 2024, PepGen employs 65 workers, which is 2% more then previous quarter.

  • When PepGen went public?

    PepGen Inc. is publicly traded company for more then 3 years since IPO on 6 May 2022.

  • What is PepGen's official website?

    The official website for PepGen is pepgen.com.

  • Where are PepGen's headquarters?

    PepGen is headquartered at 245 Main Street, Cambridge, MA.

  • How can i contact PepGen?

    PepGen's mailing address is 245 Main Street, Cambridge, MA and company can be reached via phone at +7 817970979.

PepGen company profile:

PepGen Inc.

pepgen.com
Exchange:

NASDAQ

Full time employees:

76

Industry:

Biotechnology

Sector:

Healthcare

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

245 Main Street
Cambridge, MA 02142

CIK: 0001835597
ISIN: US7133171055
CUSIP: 713317105